Genital warts testing

Genital warts are soft, flesh-colored, pink, white, or gray growths that can be flat, slightly raised, or shaped like a cauliflower (condylomata acuminata). They may be a single small bump or a cluster of multiple warts of varying sizes — typically 1 mm to several centimeters. They appear on the penis, scrotum, vulva, vaginal walls, cervix, anus, groin, or inner thighs, and can also be internal (inside the vagina, anus, or urethra). They are usually painless but may itch, bleed with friction, or cause mild burning. Flat warts on the shaft or inside the vaginal canal may not be visible without clinical examination or acetowhitening.

Sometimes — visible warts can clear spontaneously as the immune system suppresses HPV 6/11, but this can take months to years with no treatment, and you remain contagious to partners the entire time. Many warts never resolve without intervention. Because warts can cause discomfort, spread to adjacent skin via autoinoculation, and transmit the virus to partners, most clinicians recommend treatment to remove them sooner rather than waiting. Untreated warts may also grow larger or multiply. The decision to treat versus observe is shared between patient and clinician based on wart burden, location, and patient preference.

No. Genital warts are caused by <em>low-risk</em> HPV types 6 and 11, which are biologically incapable of causing cancer. The cancer-causing HPV types — primarily 16 and 18, plus 31, 33, 45, 52, and 58 — are high-risk oncogenic types that are entirely separate from the ones that cause warts. It is biologically possible to carry both low-risk (wart-causing) and high-risk (cancer-causing) HPV types simultaneously, but the warts themselves carry zero cancer risk. People with cervixes who have genital warts should continue their routine Pap/HPV cervical cancer screening on the standard schedule — not because warts increase cancer risk, but because HPV 16/18 exposure is common and cervical screening is the only way to detect those types.

Visible warts can be fully removed, but there is no treatment that cures the underlying HPV 6/11 infection — the virus can persist in surrounding tissue even after warts are gone. Recurrence happens in about 20–50% of treated cases, most often within the first 3 months after treatment. After that 3-month window, the risk decreases substantially, though warts can still return later if immunity wanes. Over time, most people's immune systems suppress HPV 6/11 enough that warts stop recurring — but this can take years and is not guaranteed for everyone. Treatment reduces the wart burden, addresses symptoms, and lowers (but doesn't eliminate) transmission risk to partners.

Clinicians strongly advise avoiding sexual contact while visible warts are present and throughout active treatment. The wart surface is highly infectious, and HPV can also shed from the surrounding skin even without direct wart contact. Condoms reduce transmission risk but do not fully protect partners because warts and infectious skin are present beyond the area a condom covers. After wart clearance, most clinicians advise avoiding unprotected sex for at least 3 months — the period of highest recurrence and likely highest viral shedding. Partners should be informed, evaluated for their own warts, and encouraged to consider HPV vaccination.

Genital warts are flesh-colored, painless (or mildly itchy) growths — often raised, rough-textured, or cauliflower-shaped — that do not blister or ulcerate. Herpes presents as clusters of small, fluid-filled blisters that break open into painful ulcers; lesions are notably tender, burning, and typically heal within 2–4 weeks. Molluscum contagiosum produces dome-shaped, pearly, smooth bumps with a characteristic central dimple (umbilication) and a waxy core — no roughness or cauliflower texture. Skin tags are smooth, soft, often hanging from a stalk (pedunculated), appear in skin folds, are not sexually transmitted, and are not infectious. All of these conditions can co-exist. Self-diagnosis is unreliable — see a clinician for a definitive diagnosis, especially for a first episode.

Not with standard OTC products. Prescription-only FDA-approved home treatments include imiquimod cream (Aldara 5%, Zyclara 3.75%), podofilox 0.5% solution or gel (Condylox), and sinecatechins 15% ointment (Veregen) — all require a clinician visit and prescription. Over-the-counter wart removers designed for hand and foot warts — including salicylic acid products and freezing kits (compound W, Dr. Scholl's, etc.) — are absolutely NOT approved or safe for genital skin. They can cause serious chemical burns, scarring, severe pain, and tissue damage. Get a clinical diagnosis first, then ask about prescription home-use options.

Warts typically appear 2–3 months after exposure to HPV 6/11, but the incubation period can range from as short as a few weeks to as long as 2 years. Because of this long and highly variable window, it is often impossible to identify the specific sexual encounter or partner responsible for the infection. The inability to pinpoint the source is clinically expected and does not imply a partner was unfaithful. The virus can also shed from skin without visible warts — so an exposure from a partner with no visible warts is entirely possible.

Not in the way there's a test for chlamydia or syphilis. Genital warts are diagnosed by a clinician examining the affected area — there is no blood test, urine test, or swab that detects genital warts or HPV 6/11 specifically. No routine HPV test exists for men or people with penises. For people with a cervix, Pap and HPV co-tests screen for high-risk cancer-causing HPV types (16, 18, etc.) — these are cancer-screening tests for different HPV types, not a genital warts test. They will not specifically identify HPV 6/11 or confirm a genital wart diagnosis.

No. Gardasil 9 does not treat warts you already have and does not clear HPV types you've already acquired. It is a preventive vaccine, most effective when given before any HPV exposure. However, if you already have genital warts, vaccination can still protect you from the other covered HPV types you have not yet encountered — including the high-risk cancer-causing types (16, 18, and five others). Getting vaccinated after a genital wart diagnosis is not pointless; it provides meaningful protection against future exposures to the six other covered types even if it won't resolve your current infection.

Genital warts often grow larger and become more numerous during pregnancy due to hormonal changes and immune adaptation. The three patient-applied prescription treatments — imiquimod (Aldara/Zyclara), podofilox (Condylox), and sinecatechins (Veregen) — are all contraindicated during pregnancy and must not be used. Safe provider-applied options include cryotherapy, TCA/BCA acid application, and surgical excision or electrocautery. There is a small risk of HPV 6/11 passing to the baby during vaginal delivery and, in rare cases, causing recurrent respiratory papillomatosis (RRP) in the child's larynx or airway. This risk does not routinely justify cesarean delivery — discuss your individual situation with an OB-GYN or maternal-fetal medicine specialist.

Genital warts are among the most contagious STI presentations: an estimated 65–70% of sexual contacts of someone with visible warts will develop them. HPV 6/11 also sheds from surrounding skin without visible warts, so transmission is possible even without active lesions. Informing sexual partners is important so they can be evaluated, seek treatment if warts are present, and consider HPV vaccination. There is no clinical partner-notification mandate for genital warts the way there is for syphilis or HIV, but disclosure supports partner health and is part of an ethical approach to sexual health.